October 21, 2015
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
“It is very encouraging to hear that the patient in question is doing
better and is no longer in critical condition. Our thoughts and wishes
for continued recovery are with her, with her family and the excellent
medical team at
GS-5734 was discovered as part of Gilead’s program to screen compounds
in its libraries for activity against a range of potential emerging
viruses, including Ebola. In collaboration with the
In animal studies conducted at USAMRIID, treatment initiated on day 3
post-infection with Ebola virus resulted in 100 percent survival of
monkeys. Data from these studies were recently presented at the annual
Ebola represents a global public health crisis, and Gilead is working with USAMRIID and a number of private and public health entities to determine next steps on how to advance evaluation of GS-5734. In the event that the compound proves to be safe and effective in humans, Gilead plans to work to enable access as broadly and quickly as possible. In the interim, the company will review any requests for compassionate access on a case by case basis.
GS-5734 is an investigational compound that has not been proven safe and effective for EVD; additionally, its clinical effect in this particular patient case cannot be determined.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
For more information on
Gilead Sciences, Inc.
Patrick O’Brien, +1 650-522-1936
Sonia Choi, +44 208 587 2497
Amy Flood, +1 650-522-5643